PGI2 SYSTEMATIC REVIEW AND META-ANALYSIS OF INFLIXIMAB, ADALIMUMAB, GOLIMUMAB, VEDOLIZUMAB, AND TOFACITINIB FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS IN ANTI-TNF-ALPHA-NAIVE PATIENTS
May 1, 2020, 00:00
10.1016/j.jval.2020.04.362
https://www.valueinhealthjournal.com/article/S1098-3015(20)30550-7/fulltext
Title :
PGI2 SYSTEMATIC REVIEW AND META-ANALYSIS OF INFLIXIMAB, ADALIMUMAB, GOLIMUMAB, VEDOLIZUMAB, AND TOFACITINIB FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS IN ANTI-TNF-ALPHA-NAIVE PATIENTS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30550-7&doi=10.1016/j.jval.2020.04.362
First page :
Section Title :
Open access? :
No
Section Order :
10231